Enterprise Value

437.1M

Cash

199.2M

Avg Qtr Burn

-31.68M

Short % of Float

3.06%

Insider Ownership

0.78%

Institutional Own.

83.77%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Ganaxolone (ZTALMY) Details
Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder

Approved

Quarterly sales

Ganaxolone Details
Tuberous sclerosis complex

Phase 3

Data readout

Ganaxolone Details
Epilepsy, Refractory Status Epilepticus

Phase 3

Data readout

Ganaxolone Details
Established Status Epilepticus

Phase 2

Interim update

Phase 1

Interim update